Investor Presentaiton
LOVVOLUS
De
JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY EFFICACY:
NONE OR MILD GLABELLAR LINE RESPONDERS
NONE OR MILD
GLABELLAR LINES
AT MAXIMUM
FROWN
Investigator +
Subject
Assessment
Pra 40U vs.
Daxi 40U Sakura 1
PERCENT OF
90
80
70
60
50
40
ཤྲཱ ཞ ༅ ➢ ཋ ཞ ¥ ཞ 8 ཋ
100
RESPONDERS
(%)
*
20
Prabot
Prabot
Daxi -
Daxi
40U
40U
40U
40U
10
(IA)
(SA)
(IA)
(SA)
0
0
30
60
60
90
06
120
150
◆ No prabot data collected between Day 2 and Day 30
*DaxxifyⓇ FDA Prescribing Information (Graph GL1) Carruthers, Plastic Reconstructive Surgery 2020 Jan; 145 (1): 45-58
Note: Results drawn from multiple studies. Caution should be used when interpreting cross-study comparisons
Baseline Demographics
Daxibotulinum
Sakura 163.2 Moderate
Prabotulinum
40U PII 70.6% Severe
1pt change
required
2 pt change
required
180
210
240
270
300
330
360
DAYS AFTER TREATMENT
22
27View entire presentation